BioAlliance Pharma to Pursue Its Strategy for the Targeted Acquisition of Complementary Products Following the Announcement of the Discontinuation of Immtech Pharmaceuticals, Inc.’ Pafuramidine Program

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris: BIO) today confirmed that it will pursue its advanced compound acquisition strategy for European oncology and HIV markets, despite Immtech Pharmaceuticals Inc.'s (AMEX: IMM) recently announced discontinuation of its pafuramidine program.